Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid

Giannis Mountzios; Evangelos Terpos; Konstantinos Syrigos; Christos Papadimitriou; Giorgos N. Papadopoulos; Aristotelis Bamias; Myron Mavrikakis; Meletios A Dimopoulos

doi:10.1016/j.trsl.2010.01.002

Back

Shared by

Meletios A Dimopoulos

Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid

Article 2010 en

Authors

GM
Giannis Mountzios
ET
Evangelos Terpos
KS
Konstantinos Syrigos

Related publications

Article2009

1086 Biochemical markers of bone remodeling as predictors of skeletal morbidity and outcome in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid

Giannis Mountzios, Meletios A Dimopoulos, A. Bamias, Myron Mavrikakis, K. Syrigos, Evangelos Terpos

Article2006

Survival in patients with multiple myeloma receiving zoledronic acid: Stratification by baseline bone alkaline phosphatase levels

James R. Berenson, N. Shirina, Y. M. Chen, Meletios A Dimopoulos

Article2009

RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases

Evangelos Terpos, Eleni Efstathiou, Dimitrios Christoulas, Μαρία Ρούσσου, Eirini Katodritou, Meletios A Dimopoulos

Letter2010

Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid

Evangelos Terpos, D. Christoulas, Panagiotis Kokkoris, Konstantinos Anargyrou, Maria Gavriatopoulou, Magdalini Migkou, Konstantinos Tsionos, Meletios A Dimopoulos

Article2012

Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: Report of 2 cases with clinical implications

Ourania Nicolatou‐Galitis, Magdalini Migkou, Amanda Psyrri, Aristotle Bamias, Dimitrios Pectasides, Theofanis Economopoulos, Judith E. Raber‐Durlacher, George Dimitriadis, Meletios A Dimopoulos

Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid

Discussion(0)

Related publications

1086 Biochemical markers of bone remodeling as predictors of skeletal morbidity and outcome in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid

Survival in patients with multiple myeloma receiving zoledronic acid: Stratification by baseline bone alkaline phosphatase levels

RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases

Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid

Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: Report of 2 cases with clinical implications